Crown Bioscience invites you to attend our San Diego symposium focused on Advanced Strategies for Translational Oncology Research. Join the discussion on new targets, technologies, and enhanced models for developing the next generation of oncology and immuno-oncology agents.

Review the breakthrough discoveries leading to the development of HUB Organoids. Explore the key features of these 3D in vitro models including organ morphology recapitulation, stability, genomic superiority, and long-term culture, as well as their main utilities in research and development.

Presented by Dr Rajendra Kumari this webinar will explore how to overcome translational challenges in CAR-T cell therapy development. She'll discuss the different preclinical models available for CAR-T and cell therapy efficacy and safety assessment including PDX, as well as a novel rare cell analysis platform for sensitive CAR-T detection.

Presented by Dr Fred Beasley this webinar will explain how to select the most appropriate models for your preclinical obesity studies, including reviewing polygenic vs monogenic models and recommendations based on drug modes of action. We'll also review best practice in obesity study design to maximize data outcomes.

Preview our poster topics now covering a wide variety of preclinical oncology and immuno-oncology platforms including tumor organoids for drug discovery and I/O drug development, orthotopic syngeneic models, and immunoprofiling data.

Presented by Dr Sylvia Boj, Hubrecht Organoid Technology this webinar reviews the development and application of HUB Organoids. Explore the many advantages of HUB Organoids within 3D in vitro modeling, including direct clinical relevance and immuno-oncology applications.

Learn more about NHPs as a valuable early-stage preclinical platform for non-GLP exploratory toxicology studies. Explore the robust data these studies generate in a rapid, flexible, and cost-effective manner to assess immunotherapy safety and de-risk future clinical trials.

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.

We presented posters on our unique translational NASH model at the ADA Scientific Sessions this year. Download our latest data on NASH induction in the dysmetabolic MS-NASH mouse (formerly FATZO), and accelerated disease induction resulting in a model featuring both severe fibrosis and dysmetabolism.